ITUS (ITUS) Reaches $3.30 After 3.00% Down Move; Datawatch (DWCH) Sentiment Is 0.9

February 15, 2018 - By Kurt Siggers

The stock of ITUS Corporation (NASDAQ:ITUS) is a huge mover today! The stock decreased 8.47% or $0.305 during the last trading session, reaching $3.295. About 358,138 shares traded. ITUS Corporation (NASDAQ:ITUS) has declined 67.95% since February 15, 2017 and is downtrending. It has underperformed by 84.65% the S&P500.The move comes after 7 months negative chart setup for the $54.73 million company. It was reported on Feb, 15 by Barchart.com. We have $3.20 PT which if reached, will make NASDAQ:ITUS worth $1.64M less.

Datawatch Corporation designs, develops, markets, and distributes business computer software products to self-service data preparation and visual data discovery markets in the United States and internationally. The company has market cap of $124.76 million. The Company’s software solutions allow organizations to access, analyze, and visualize their information. It currently has negative earnings. The companyÂ’s products include Datawatch Monarch, a self-service data preparation tool to explore, manipulate, and merge new data sources; Datawatch Panopticon that enables real-time preparation of streaming data for data analysis; and Datawatch Report Mining Server, a Web report analytics solution that integrates with existing enterprise content management system for unlocking the corporate data.




G2 Investment Partners Management Llc holds 4.67% of its portfolio in Datawatch Corporation for 1.02 million shares. Archon Capital Management Llc owns 66,353 shares or 0.41% of their US portfolio. Moreover, Eam Investors Llc has 0.37% invested in the company for 240,709 shares. The Illinois-based Oberweis Asset Management Inc has invested 0.32% in the stock. Essex Investment Management Co Llc, a Massachusetts-based fund reported 200,051 shares.

The stock decreased 1.94% or $0.2 during the last trading session, reaching $10.1. About 11,870 shares traded. Datawatch Corporation (DWCH) has risen 56.31% since February 15, 2017 and is uptrending. It has outperformed by 39.61% the S&P500.

ITUS Corporation funds, develops, acquires, and licenses emerging technologies in the areas of biotechnology. The company has market cap of $54.73 million. The company, through its subsidiary, Anixa Diagnostics Corporation, is developing a platform called Cchek, a series of non-invasive, blood tests for the early detection of solid tumor based cancers. It currently has negative earnings. It has a collaborative research agreement with The Wistar Institute for the development and validation of Cchek.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.